Research programme : Purinergic P1 receptor modulators - Lewis and Clark Pharmaceuticals

Drug Profile

Research programme : Purinergic P1 receptor modulators - Lewis and Clark Pharmaceuticals

Alternative Names: Adenosine receptor modulators - Lewis and Clark Pharmaceuticals

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lewis and Clark Pharmaceuticals
  • Developer Lewis and Clark Pharmaceuticals; National Institutes of Health (USA)
  • Class Anti-inflammatories; Antiasthmatics; Antibacterials; Antiglaucomas; Antineoplastics
  • Mechanism of Action Adenosine A2A receptor agonists; Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Purinergic P1 receptor modulators; Purinergic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Atherosclerosis; Autoimmune disorders; Cancer; Clostridium infections; Fatty liver; Glaucoma; Graft-versus-host disease; Inflammation; Pain

Most Recent Events

  • 23 Oct 2017 Inspyr Therapeutics and National Institutes of Health (USA) enter into research collaboration to evaluate adenosine receptor modulators for prevention of Graft versus host disease
  • 23 Oct 2017 Preclinical trials in Graft-versus-host disease (Prevention) in USA (unspecified route)
  • 02 Oct 2017 Inspyr Therapeutics enters into a research collaboration agreement with University of Virginia School of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top